MA
COLL icon

Mutual Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Mutual Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,252
Closed -$702K – 1009
2023
Q1 		$702K Buy
+29,252
New +$776K 0.03% 527

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Mutual Advisors's COLL Position: Q2 2023 in Review

Mutual Advisors sold out of Collegium Pharmaceutical (COLL) in Q2 2023, closing a stake of 29,252 shares — an estimated $702K sold.

Mutual Advisors first reported a position in COLL in Q1 2023 and held it in 1 quarter. The position peaked at $702K in Q1 2023. 178 funds tracked by Wall St. Rank hold COLL as of Q2 2023.

  • Mutual Advisors reported no remaining Collegium Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Mutual Advisors sold 29,252 Collegium Pharmaceutical shares in Q2 2023, an estimated $702K.
  • Mutual Advisors first reported a position in Collegium Pharmaceutical in Q1 2023 and held it in 1 quarter.
  • Mutual Advisors's Collegium Pharmaceutical position peaked at $702K in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2023.

Based on Mutual Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.